NCT03530397

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Active, enrolled Phase 1 Last updated 24 June 2024

What this trial tests

Phase 1 trial testing MEDI5752 in Selected Advanced Solid Tumors in 401 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

24 April 2018

Primary endpoint
30 December 2025

30 December 2025

Quick facts

Lead sponsor	MedImmune LLC
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	401
Start date	24 April 2018
Primary completion	30 December 2025
Estimated completion	30 December 2025
Sites	40 locations across France, Italy, Netherlands, Taiwan, South Korea, Australia, Portugal, United States

Drugs / interventions tested

• MEDI5752
• Pemetrexed — full drug profile →
• Carboplatin (Carboplatin) — full drug profile →
• Pembrolizumab (pembrolizumab) — full drug profile →
• Paclitaxel or Nab-Paclitaxel — full drug profile →

Conditions studied

• Selected Advanced Solid Tumors — all drugs for Selected Advanced Solid Tumors →

Sponsor

MedImmune LLC — full company profile →

Who can join

Adults 18 to 120, any sex, with Selected Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate MEDI5752 and carboplatin and pemetrexed or paclitaxel or nab-paclitaxel in adult subjects with advanced solid tumors, when administered as a single agent or combined with chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Clinical cancer immunotherapy: Current progress and prospects.
   Liu C, Yang M, Zhang D, Chen M, et al · · 2022 · cited 147× · PMID 36304470 · DOI 10.3389/fimmu.2022.961805
2. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets.
   Luo XY, Wu KM, He XX. · · 2021 · cited 144× · PMID 34006331 · DOI 10.1186/s13046-021-01968-w
3. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
   Wei J, Yang Y, Wang G, Liu M. · · 2022 · cited 127× · PMID 36389699 · DOI 10.3389/fimmu.2022.1035276
4. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.
   Cheng W, Kang K, Zhao A, Wu Y. · · 2024 · cited 110× · PMID 39068460 · DOI 10.1186/s13045-024-01581-2
5. Biology drives the discovery of bispecific antibodies as innovative therapeutics.
   Nie S, Wang Z, Moscoso-Castro M, D'Souza P, et al · · 2020 · cited 79× · PMID 33928225 · DOI 10.1093/abt/tbaa003
6. Recent advances and challenges of bispecific antibodies in solid tumors.
   Wu Y, Yi M, Zhu S, Wang H, et al · · 2021 · cited 64× · PMID 34922633 · DOI 10.1186/s40164-021-00250-1
7. Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.
   Meng L, Collier KA, Wang P, Li Z, et al · · 2023 · cited 48× · PMID 38201238 · DOI 10.3390/cells13010034
8. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
   Zhang T, Lin Y, Gao Q. · · 2023 · cited 47× · PMID 36971124 · DOI 10.20892/j.issn.2095-3941.2023.0002